Alexandre de Matos Soeiro

TL;DR: In this paper, the authors compared the efficacy and safety of therapeutic versus prophylactic anticoagulation in patients hospitalised with COVID-19 in 31 sites in Brazil, and found that in the case of stable patients, in-hospital oral rivaroxaban (20 mg or 15 mg daily) or initial subcutaneous enoxaparin (1 mg/kg twice per day) or intravenous unfractionated heparin (to achieve a 0·3-0·7 IU/mL anti-Xa concentration) for clinically unstable patients, followed

TL;DR: Among patients hospitalized with Covid-19 pneumonia, tofacitinib led to a lower risk of death or respiratory failure through day 28 than placebo, and the proportional odds of having a worse score on the eight-level ordinal scale with tofacinib, as compared with placebo.

TL;DR: Integration of ADD-RS with D-dimer may be considered to standardize diagnostic rule out of AAS to help physicians to balance these risks of misdiagnosis and overtesting.

TL;DR: Among patients with AHF, a strategy of early intensive and sustained vasodilation, compared with usual care, did not significantly improve a composite outcome of all-cause mortality and AHF rehospitalization at 180 days.

TL;DR: Diretrizes da Sociedade Brasileira de Cardiologia sobre Angina Instavel and Infarto Agudo do Miocardio sem Supradesnivel do Segmento ST.